Envoy Medical, Inc. 8-K

What Happened Envoy Medical, Inc. filed an 8-K (May 22, 2026) reporting that Nasdaq notified the company it failed to meet the $1.00 minimum bid-price requirement under Nasdaq Listing Rule 5550(a)(2). The initial notice was issued on November 19, 2025 and gave the company a 180‑day compliance period ending May 18, 2026. Although the company did not regain compliance by that date, on May 19, 2026 Nasdaq granted a second 180‑day compliance period ending November 16, 2026. The company told Nasdaq it intends to cure the deficiency if needed, including by effecting a reverse stock split.

Key Details

• Nasdaq Listing Rule cited: 5550(a)(2) (minimum $1.00 bid) and compliance process per Rule 5810(c)(3)(A).
• Original notice: November 19, 2025; initial compliance deadline: May 18, 2026.
• Second compliance period: 180 days, through November 16, 2026 (notice received May 19, 2026).
• To regain compliance the closing bid must be ≥ $1.00 for at least ten consecutive business days; the company has notified Nasdaq it may use a reverse stock split if necessary. The notice did not affect the listing immediately.

Why It Matters This filing signals a continued risk that Envoy’s Class A common stock could be delisted from the Nasdaq Capital Market if the company does not cure the bid‑price deficiency by November 16, 2026. For investors, delisting could reduce liquidity and change where the shares trade. The company’s stated potential remedy (a reverse stock split) is a common tactic to raise per‑share price but would alter share count and could affect trading dynamics. Shareholders should monitor share price, company updates, and any proposals related to a reverse split or other corrective actions.